Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment

Adv Biol Regul. 2013 Jan;53(1):146-55. doi: 10.1016/j.jbior.2012.09.004. Epub 2012 Sep 16.

Authors

William H Chappell¹, Stephen L Abrams, Kristin M Stadelman, Michelle M LaHair, Richard A Franklin, Lucio Cocco, Camilla Evangelisti, Francesca Chiarini, Alberto M Martelli, Linda S Steelman, James A McCubrey

Affiliation

¹ Department of Microbiology & Immunology, Brody School of Medicine, East Carolina University, 600 Moye Blvd., Greenville, NC 27834, USA.

PMID: 23073564
DOI: 10.1016/j.jbior.2012.09.004

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Acute-Phase Proteins / agonists
Acute-Phase Proteins / genetics*
Acute-Phase Proteins / metabolism
Antibiotics, Antineoplastic / pharmacology*
Cell Line, Tumor
Cell Survival / drug effects
Doxorubicin / pharmacology*
Drug Resistance, Neoplasm / drug effects
Female
Gene Expression Regulation, Neoplastic / drug effects*
Humans
Inhibitory Concentration 50
Lipocalin-2
Lipocalins / agonists
Lipocalins / genetics*
Lipocalins / metabolism
Male
Matrix Metalloproteinase 9 / genetics*
Matrix Metalloproteinase 9 / metabolism
Paclitaxel / pharmacology*
Proto-Oncogene Proteins / agonists
Proto-Oncogene Proteins / genetics*
Proto-Oncogene Proteins / metabolism
Signal Transduction / drug effects

Substances

Acute-Phase Proteins
Antibiotics, Antineoplastic
LCN2 protein, human
Lipocalin-2
Lipocalins
Proto-Oncogene Proteins
Doxorubicin
Matrix Metalloproteinase 9
Paclitaxel